Research
Hormonal
Low serum levels of IGF-I are associated with the severity of NAFLD, including inflammation, hepatocyte ballooning, and fibrosis, even in non-GHD patients.
If you have NAFLD, your IGF-I levels might be low, which correlates with more severe liver damage. While this doesn't mean you should take IGF-I supplements (which are not standard), it highlights the importance of the GH-IGF-I axis in liver health.
GoodQualifiesHIGH confidence
Lower serum IGF-I levels were associated with the severity of inflammation, hepatocyte ballooning, and fibrosis in patients with NAFLD.
Why this rating
Based on multiple human studies cited in the review showing consistent associations.
Source
The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver
Yutaka Takahashi · International Journal of Molecular Sciences · 2017
DOI 10.3390/ijms18071447
narrative_reviewCited 188×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Growth hormone (GH) replacement therapy in adults with growth hormone deficiency (GHD) improves non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) by reducing visceral adipose tissue and directly decreasing hepatic lipogenesis.Moderate
- Insulin-like Growth Factor-I (IGF-I) administration ameliorates liver fibrosis and NASH by inducing cellular senescence in hepatic stellate cells (HSCs), thereby inactivating them and limiting fibrosis progression.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →